Olaparib Out: AstraZeneca Withdraws Key Cancer Drug for Advanced Cases

AstraZeneca Pharma India Ltd has relinquished its marketing authorization for Olaparib tablets (traded as Lynparza) for certain cancer indications in India. This action comes after a directive from the Drug Controller General of India (DCGI) to take the drug off the market for certain patient populations because of fears of possible adverse effects and overall survival results. The firm explained that the discontinuation is commercial in nature and has nothing to do with the drug's safety or efficacy in other indications.

 

Key Points

Sources Economic Times Times of India CNBC TV18 Hindustan Times